Literature DB >> 15608895

[Study of inequalities in hospital mortality using the Charlson comorbidity index].

Nelson Iucif1, Juan S Yazlle Rocha.   

Abstract

OBJECTIVE: The evaluation of quality and equity in healthcare attendance requires adequate study methods and information systems. Thus, this study was performed with the objective of comparing mortality among elderly patients attended within the private network and within the Brazilian national health system (SUS).
METHOD: An information system that recorded causes of hospitalization and associated diseases (comorbidity) in relation to public and private hospital admissions was utilized. The hospitalization of 21,695 patients in Ribeirão Preto, State of Sao Paulo, in 1998 and 1999 was studied. These patients had diseases of the circulatory and respiratory systems. Analysis was done via the methodology put forward by Charlson, in which comorbidities are scored to give the Charlson comorbidity index and age over 50 years (per decade) is scored to give the Charlson comorbidity-age index. The patients were stratified according to comorbidity and decade of age over 50 years, with separation of hospitalizations via SUS from those via the private network (non-SUS). The coefficient of hospital mortality was calculated for each stratum.
RESULTS: It was observed that the risk of death increased almost sixfold when the number of associated diseases increased. The risk of death for SUS patients was more than twice the risk for non-SUS patients (relative risk: 2.12). Significant differences between SUS and non-SUS patients were found by associating the patient's comorbidity with decade of age. When the risk of death was very low or very high, there were no statistical differences between SUS and non-SUS patients. In other, intermediate situations, precisely where the attendance might make a difference, the mortality among SUS patients was more than twice as great (relative risk: 2.14).
CONCLUSIONS: The difference in mortality between SUS and non-SUS patients, according to Charlson's criteria, is significant among patients of intermediate risk, for whom the care is most important. The Charlson comorbidity index correlates with hospital mortality.

Entities:  

Mesh:

Year:  2004        PMID: 15608895     DOI: 10.1590/s0034-89102004000600005

Source DB:  PubMed          Journal:  Rev Saude Publica        ISSN: 0034-8910            Impact factor:   2.106


  4 in total

1.  Mortality Predictors and Associated Factors in Patients in the Intensive Care Unit: A Cross-Sectional Study.

Authors:  Fernanda G de M Soares Pinheiro; Eduesley Santana Santos; Íkaro Daniel de C Barreto; Carleara Weiss; Andreia C Vaez; Jussiely C Oliveira; Matheus S Melo; Francilene A Silva
Journal:  Crit Care Res Pract       Date:  2020-08-01

2.  Factors Affecting Sick Leave Duration for Non-Work-Related Temporary Disabilities in Brazilian University Public Servants.

Authors:  Adriano Dias; Juan Gómez-Salgado; João Marcos Bernardes; Carlos Ruiz-Frutos
Journal:  Int J Environ Res Public Health       Date:  2018-09-27       Impact factor: 3.390

3.  Is the number of previous hospitalizations associated with increased in-hospital mortality after hip fracture in a developing country?

Authors:  Helen Regina Mota Machareth de Morais; Edison Iglesias de Oliveira Vidal; Claudia Medina Coeli; Rejane Sobrino Pinheiro
Journal:  PLoS One       Date:  2020-10-09       Impact factor: 3.240

4.  Whole-genome sequence-informed MALDI-TOF MS diagnostics reveal importance of Klebsiella oxytoca group in invasive infections: a retrospective clinical study.

Authors:  Aline Cuénod; Daniel Wüthrich; Helena M B Seth-Smith; Chantal Ott; Christian Gehringer; Frédéric Foucault; Roxanne Mouchet; Ali Kassim; Gunturu Revathi; Deborah R Vogt; Stefanie von Felten; Stefano Bassetti; Sarah Tschudin-Sutter; Timm Hettich; Götz Schlotterbeck; Christina Homberger; Carlo Casanova; Jacob Moran-Gilad; Orli Sagi; Belén Rodríguez-Sánchez; Franco Müller; Martina Aerni; Valeria Gaia; Helke van Dessel; Greetje A Kampinga; Claudia Müller; Claudia Daubenberger; Valentin Pflüger; Adrian Egli
Journal:  Genome Med       Date:  2021-09-13       Impact factor: 11.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.